Orchestra BioMed Holdings, Inc. cash flow to debt ratio of -306.88% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Orchestra BioMed Holdings, Inc.'s free cash flow has increased -2.74% from $-50.85M last year to $-49.45M, signaling increasing performance

Orchestra BioMed Holdings, Inc.'s debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability.

Orchestra BioMed Holdings, Inc.'s debt has decreased relative to shareholder equity from 0.50 last year to 0.07 today, signaling strengthened financials

Orchestra BioMed Holdings, Inc. has a net cash position, so leverage is healthy.

Orchestra BioMed Holdings, Inc.'s interest coverage ratio is -27.63, which means that the company struggles to meet interest obligations, signaling financial risk.

Orchestra BioMed Holdings, Inc.'s profit margin has increased (-92.02%) in the last year from -2.31K% to -184.60%, signaling increasing performance

Orchestra BioMed Holdings, Inc.'s short-term assets of $107.91M exceed its short-term liabilities of $16.74M

Orchestra BioMed Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Orchestra BioMed Holdings, Inc.'s return on equity of -133.09%, is lower than 15.00%, indicating bad performance

Orchestra BioMed Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Orchestra BioMed Holdings, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Orchestra BioMed Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Orchestra BioMed Holdings, Inc. has negative free cash flow, indicating cash burn

Orchestra BioMed Holdings, Inc.'s yearly earnings has increased -13.64% since last year from $-61.02M to $-52.70M, signaling increasing performance

Orchestra BioMed Holdings, Inc.'s yearly revenue has increased 1.17K% since last year from $2.64M to $33.48M, signaling increasing performance

ROIC -56.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Orchestra BioMed Holdings, Inc.'s 3-year revenue CAGR of 111.62% is positive, indicating growing revenue over the past 3 years

Orchestra BioMed Holdings, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Orchestra BioMed Holdings, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Orchestra BioMed Holdings, Inc. has insufficient data to evaluate this check.

Orchestra BioMed Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Orchestra BioMed Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Orchestra BioMed Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Orchestra BioMed Holdings, Inc. has insufficient data to evaluate this check.

Orchestra BioMed Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Orchestra BioMed Holdings, Inc. has a price-to-book ratio of 9.67x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Orchestra BioMed Holdings, Inc. has a price-to-sales ratio of 8.90x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue